BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol 2019;10:645-51. [PMID: 31392045 DOI: 10.21037/jgo.2019.01.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Marini F, Giusti F, Tonelli F, Brandi ML. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. Int J Mol Sci 2021;22:4041. [PMID: 33919851 DOI: 10.3390/ijms22084041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marini F, Giusti F, Tonelli F, Brandi ML. Multiple endocrine neoplasia type 1: a review of current diagnostic and treatment approaches. Expert Opinion on Orphan Drugs 2020;8:367-77. [DOI: 10.1080/21678707.2020.1811086] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dai C, Liang S, Sun B, Li Y, Kang J. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front Oncol 2021;11:773905. [PMID: 34869016 DOI: 10.3389/fonc.2021.773905] [Reference Citation Analysis]
4 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
5 Lewis MA. Hereditary Syndromes in Neuroendocrine Tumors. Curr Treat Options Oncol 2020;21:50. [PMID: 32350690 DOI: 10.1007/s11864-020-00749-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gläsker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther 2020;13:5669-90. [PMID: 32606780 DOI: 10.2147/OTT.S190753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]